Neuclone Makes Progress With Ustekinumab Trial
Australian Firm Hails Phase I Results For Stelara Rival
Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.
You may also be interested in...
Bio-Thera Kicks Off Ustekinumab Trial
China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.
NeuClone Reveals Rivals To Opdivo And Keytruda
Australia’s NeuClone has revealed further details of its pipeline, offering an update that includes a glimpse at two further biosimilar projects that are in active development.
Meiji And Dong-A Start European Ustekinumab Trial
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.